AtriCure to Participate in Upcoming Investor Conferences

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming investor conferences.

AtriCure’s management is scheduled to participate in a fireside discussion at the UBS Global Healthcare Conference on Monday, November 10, 2025, at 2:00 pm Eastern Standard Time.

AtriCure’s management is also scheduled to participate in a fireside discussion at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 am Eastern Standard Time.

Interested parties may access a live audio webcast of both presentations by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

About AtriCure
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® and cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac, thoracic and amputation procedures. For more information, visit AtriCure.com or follow us on X @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251027490824/en/

Angie Wirick
AtriCure, Inc.
Chief Financial Officer
(513) 755-5334
[email protected]

Marissa Bych
Gilmartin Group
Investor Relations
[email protected]

Source: AtriCure, Inc.

You May Also Be Interested In

• Hyve Solutions Expands Manufacturing Footprint With Reno and North Las Vegas Campuses
• The Inner Circle acknowledges V. Ray Cordry, Jr., DO as a 2026 Preferred Psychiatrist
• Saba Capital Announces Name Change of the Saba Closed-End Funds ETF to Saba Opportunistically Hedged Closed-End Funds ETF